INVESTOR RELATIONS
(OTCPK: BWVI)
CORPORATE OVERVIEW
Psycheceutical Bioscience Inc. (OTCPK: BWVI) is a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments. Powered by a team of FDA drug development veterans, leading mental health scientists, and a network of international partners, Psycheceutical is on a mission to develop precision dosing technologies and more effective tools to provide the safe and effective delivery of psychedelic pharmaceutical medicines.
Our next-generation patented delivery technologies, via systemic and non-systemic routes of administration, are expected to allow psychedelics to be administered without unwanted side effects and toxicity, providing direct and profound benefits to those suffering from mental health disorders.
WHY INVEST
2 Patented Drug
Delivery Technologies
designed to increase the safety and efficacy of psychedelic therapeutics while eliminating hallucinations and side effects.
2 Active Clinical
Research Programs
NeuroDirect™ ketamine topical for PTSD — clinical trials Q2 2023.
Second drug for the treatment of addiction in pre-clinical stage.
An Experienced,
Visionary Team
consisting of medical specialists, biotechnology scientists, FDA regulatory advisors, psychedelic industry insiders, and business development experts.
LATEST ANNOUNCEMENTS
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD
Psycheceutical enters into agreement with iNGENū to conduct human clinical trials of NeuroDirect™ ketamine topical in Australia
Read More EVENTS + MEDIA
Latest Events
- Annual Cannabis & Psychedelics Investment Summit
February 27, 2023 | Coral Gables, FL
- Cannadelic Conference
February 2-4, 2023 | Miami
- Microdose Wonderland
November 5, 2022 | Miami
Upcoming Events
- Benzinga Psychedelics Capital Conference
April 13, 2023 | Miami Beach
- Psychedelic Therapeutics and Drug Development Conference
May 16-17, 2023 | San Francisco